{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T22:13:49Z","timestamp":1787004829801,"version":"build-2736575974"},"reference-count":103,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T00:00:00Z","timestamp":1758326400000},"content-version":"am","delay-in-days":415,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100017784","name":"Gilead Research Scholars Program","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017784","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015803","name":"BC Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015803","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1053\/j.seminhematol.2024.05.005","type":"journal-article","created":{"date-parts":[[2024,5,31]],"date-time":"2024-05-31T12:43:35Z","timestamp":1717159415000},"page":"221-228","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Molecular biomarkers in classic Hodgkin lymphoma"],"prefix":"10.1053","volume":"61","author":[{"given":"Makoto","family":"Kishida","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manabu","family":"Fujisawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Steidl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminhematol.2024.05.005_bib0001","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.05.005_bib0002","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/s41572-020-0189-6","article-title":"Hodgkin lymphoma","volume":"6","author":"Connors","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"10.1053\/j.seminhematol.2024.05.005_bib0003","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1182\/blood-2014-11-610436","article-title":"Flow sorting and exome sequencing reveal the oncogenome of primary Hodgkin and Reed-Sternberg cells","volume":"125","author":"Reichel","year":"2015","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2024.05.005_bib0004","doi-asserted-by":"crossref","unstructured":"Tiacci E, Ladewig E, Schiavoni G, et al. Pervasive mutations of JAK-STAT pathway genes in classical Hodgkin lymphoma. 2018;131:2454\u20132465","DOI":"10.1182\/blood-2017-11-814913"},{"key":"10.1053\/j.seminhematol.2024.05.005_bib0005","doi-asserted-by":"crossref","first-page":"4065","DOI":"10.1182\/bloodadvances.2019001012","article-title":"Genomic analyses of flow-sorted Hodgkin Reed-Sternberg cells reveal complementary mechanisms of immune evasion","volume":"3","author":"Wienand","year":"2019","journal-title":"Blood Adv"},{"key":"10.1053\/j.seminhematol.2024.05.005_bib0006","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1158\/2643-3230.BCD-22-0128","article-title":"Molecular evolution of classic Hodgkin lymphoma revealed through whole-genome sequencing of Hodgkin and Reed Sternberg Cells","volume":"4","author":"Maura","year":"2023","journal-title":"Blood Cancer Discov"},{"key":"10.1053\/j.seminhematol.2024.05.005_bib0007","doi-asserted-by":"crossref","unstructured":"Carey CD, Gusenleitner D, Lipschitz M, et al. Topological analysis reveals a PD-L1-associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma. 2017;130:2420\u20132430.","DOI":"10.1182\/blood-2017-03-770719"},{"key":"10.1053\/j.seminhematol.2024.05.005_bib0008","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1182\/blood-2018-04-843714","article-title":"Mass cytometry of Hodgkin lymphoma reveals a CD4+ regulatory T-cell\u2013rich and exhausted T-effector microenvironment","volume":"132","author":"Cader","year":"2018","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2024.05.005_bib0009","first-page":"2059","article-title":"The microenvironmental niche in classic Hodgkin lymphoma is enriched for CTLA-4\u2013positive T cells that are PD-1\u2013negative","volume":"134","author":"Patel","year":"2019","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2024.05.005_bib0010","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1158\/2159-8290.CD-19-0680","article-title":"Single-cell transcriptome analysis reveals disease-defining t-cell subsets in the tumor microenvironment of classic Hodgkin lymphoma","volume":"10","author":"Aoki","year":"2020","journal-title":"Cancer Discov"},{"key":"10.1053\/j.seminhematol.2024.05.005_bib0011","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1038\/s41591-020-1006-1","article-title":"A peripheral immune signature of responsiveness to PD-1 blockade in patients with classical Hodgkin lymphoma","volume":"26","author":"Cader","year":"2020","journal-title":"Nat Med"},{"key":"10.1053\/j.seminhematol.2024.05.005_bib0012","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2105822118","article-title":"Single-cell profiling reveals the importance of CXCL13\/CXCR5 axis biology in lymphocyte-rich classic Hodgkin lymphoma","volume":"118","author":"Aoki","year":"2021","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1053\/j.seminhematol.2024.05.005_bib0013","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2022.2033433","article-title":"CD4+ T cells in classical Hodgkin lymphoma express exhaustion associated transcription factors TOX and TOX2","volume":"11","author":"Veldman","year":"2022","journal-title":"Oncoimmunology"},{"key":"10.1053\/j.seminhematol.2024.05.005_bib0014","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1200\/JCO.23.01115","article-title":"Spatially Resolved Tumor Microenvironment Predicts Treatment Outcomes in Relapsed\/Refractory Hodgkin Lymphoma","volume":"42","author":"Aoki","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2024.05.005_bib0015","doi-asserted-by":"crossref","unstructured":"Dores GM, Curtis RE, Dalal NH, et al. Cause-specific mortality following initial chemotherapy in a population-based cohort of patients with classical Hodgkin Lymphoma, 2000-2016. 2020;38:4149\u20134162.","DOI":"10.1200\/JCO.20.00264"},{"key":"10.1053\/j.seminhematol.2024.05.005_bib0016","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1182\/blood-2016-09-740332","article-title":"Risk of heart failure in survivors of Hodgkin lymphoma: effects of cardiac exposure to radiation and anthracyclines","volume":"129","author":"van Nimwegen","year":"2017","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2024.05.005_bib0017","doi-asserted-by":"crossref","first-page":"e492","DOI":"10.1016\/S2352-3026(15)00153-2","article-title":"Cardiovascular disease after treatment for Hodgkin's lymphoma: an analysis of nine collaborative EORTC-LYSA trials","volume":"2","author":"Maraldo","year":"2015","journal-title":"Lancet Haematol"},{"key":"10.1053\/j.seminhematol.2024.05.005_bib0018","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1200\/JCO.2015.63.4444","article-title":"Radiation dose-response relationship for risk of coronary heart disease in survivors of Hodgkin Lymphoma","volume":"34","author":"van Nimwegen","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2024.05.005_bib0019","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1002\/ijc.34552","article-title":"Reproduction patterns among classical Hodgkin lymphoma survivors treated with BEACOPP and ABVD in Sweden, Denmark and Norway\u2014a population-based matched cohort study","volume":"153","author":"Entrop","year":"2023","journal-title":"Int J Cancer"},{"key":"10.1053\/j.seminhematol.2024.05.005_bib0020","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa1510093","article-title":"Adapted treatment guided by interim PET-CT scan in advanced Hodgkin's lymphoma","volume":"374","author":"Johnson","year":"2016","journal-title":"New Engl J Med"},{"key":"10.1053\/j.seminhematol.2024.05.005_bib0021","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1182\/blood-2018-05-852129","article-title":"Outcome-based interpretation of early interim PET in advanced-stage Hodgkin lymphoma","volume":"132","author":"Kobe","year":"2018","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2024.05.005_bib0022","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1200\/JCO.2016.68.6394","article-title":"Early positron emission tomography response-adapted treatment in stage I and II Hodgkin lymphoma: final results of the randomized EORTC\/LYSA\/FIL H10 Trial","volume":"35","author":"Andr\u00e9","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2024.05.005_bib0023","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1182\/blood-2018-08-870915","article-title":"Serum levels of TARC, MDC, IL-10, and soluble CD163 in Hodgkin lymphoma: a SWOG S0816 correlative study","volume":"133","author":"Hsi","year":"2019","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2024.05.005_bib0024","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.1200\/JCO.2013.53.5229","article-title":"Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group","volume":"32","author":"Barrington","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2024.05.005_bib0025","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1182\/blood.2022015851","article-title":"The International Consensus classification of mature lymphoid neoplasms: a report from the Clinical Advisory Committee","volume":"140","author":"Campo","year":"2022","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2024.05.005_bib0026","doi-asserted-by":"crossref","first-page":"2987","DOI":"10.1182\/blood.2019004044","article-title":"How I treat nodular lymphocyte-predominant Hodgkin lymphoma","volume":"136","author":"Eichenauer","year":"2020","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2024.05.005_bib0027","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.3324\/haematol.2021.278427","article-title":"Evolutionary clonal trajectories in nodular lymphocyte-predominant Hodgkin lymphoma with high risk of transformation","volume":"106","author":"Paschold","year":"2021","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2024.05.005_bib0028","doi-asserted-by":"crossref","first-page":"3601","DOI":"10.1200\/JCO.2003.03.023","volume":"21","author":"Engert","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2024.05.005_bib0029","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1200\/JCO.2005.05.2746","article-title":"Combined-modality therapy for clinical stage I or II Hodgkin's lymphoma: long-term results of the European organisation for research and treatment of cancer H7 randomized controlled trials","volume":"24","author":"Noordijk","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2024.05.005_bib0030","doi-asserted-by":"crossref","first-page":"4634","DOI":"10.1200\/JCO.2005.09.085","article-title":"Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group","volume":"23","author":"Meyer","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2024.05.005_bib0031","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1056\/NEJM199811193392104","article-title":"A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease","volume":"339","author":"Hasenclever","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2024.05.005_bib0032","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2024.05.005_bib0033","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1111\/bjh.13634","article-title":"Evaluation of the International prognostic score (IPS-7) and a simpler prognostic score (IPS-3) for advanced Hodgkin lymphoma in the modern era","volume":"171","author":"Diefenbach","year":"2015","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2024.05.005_bib0034","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa1000067","article-title":"Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma","volume":"363","author":"Engert","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2024.05.005_bib0035","doi-asserted-by":"crossref","first-page":"4234","DOI":"10.1200\/JCO.2010.33.9549","volume":"29","author":"Borchmann","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2024.05.005_bib0036","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1056\/NEJMoa1708984","article-title":"Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin's lymphoma","volume":"378","author":"Connors","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2024.05.005_bib0037","doi-asserted-by":"crossref","unstructured":"Herrera AF, LeBlanc ML, Castellino SM, et al. SWOG S1826, a randomized study of nivolumab(N)-AVD versus brentuximab vedotin(BV)-AVD in advanced stage (AS) classic Hodgkin lymphoma (HL). 2023;41:17.","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA4"},{"key":"10.1053\/j.seminhematol.2024.05.005_bib0038","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1001\/jamaoncol.2020.0750","article-title":"Efficacy of nivolumab and AVD in early-stage unfavorable classic Hodgkin lymphoma: the randomized phase 2 German Hodgkin Study Group NIVAHL trial","volume":"6","author":"Br\u00f6ckelmann","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1053\/j.seminhematol.2024.05.005_bib0039","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1067289","article-title":"Advances in the treatment of Hodgkin lymphoma: current and future approaches","volume":"13","author":"Ullah","year":"2023","journal-title":"Front Oncol"},{"key":"10.1053\/j.seminhematol.2024.05.005_bib0040","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(15)60165-9","article-title":"Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"385","author":"Moskowitz","year":"2015","journal-title":"The Lancet"},{"key":"10.1053\/j.seminhematol.2024.05.005_bib0041","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1056\/NEJMoa2206660","article-title":"Brentuximab vedotin with chemotherapy in pediatric high-risk Hodgkin's lymphoma","volume":"387","author":"Castellino","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2024.05.005_bib0042","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1089\/jayao.2015.0067","article-title":"Cardiac mortality in children and adolescents with Hodgkin's lymphoma: a surveillance, epidemiology and end results analysis","volume":"5","author":"Amini","year":"2016","journal-title":"J Adolesc Young Adult Oncol"},{"key":"10.1053\/j.seminhematol.2024.05.005_bib0043","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1016\/S1470-2045(16)30215-7","article-title":"Cumulative burden of cardiovascular morbidity in paediatric, adolescent, and young adult survivors of Hodgkin's lymphoma: an analysis from the St Jude Lifetime Cohort Study","volume":"17","author":"Bhakta","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.seminhematol.2024.05.005_bib0044","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1038\/s41571-023-00799-2","article-title":"Quantitative PET-based biomarkers in lymphoma: getting ready for primetime","volume":"20","author":"Alderuccio","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1053\/j.seminhematol.2024.05.005_bib0045","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/nrclinonc.2017.78","article-title":"Evolution of lymphoma staging and response evaluation: current limitations and future directions","volume":"14","author":"Cunningham","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1053\/j.seminhematol.2024.05.005_bib0046","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1182\/blood-2016-05-718528","article-title":"Refinement of the Lugano classification lymphoma response criteria in the era of immunomodulatory therapy","volume":"126","author":"Cheson","year":"2016","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2024.05.005_bib0047","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1309\/7371XK6F6P7474XX","article-title":"Identification and purification of classical Hodgkin cells from lymph nodes by flow cytometry and flow cytometric cell sorting","volume":"126","author":"Fromm","year":"2006","journal-title":"Am J Clin Pathol"},{"key":"10.1053\/j.seminhematol.2024.05.005_bib0048","doi-asserted-by":"crossref","first-page":"3530","DOI":"10.1182\/blood-2012-06-439570","article-title":"Gene expression profiling of microdissected Hodgkin Reed-Sternberg cells correlates with treatment outcome in classical Hodgkin lymphoma","volume":"120","author":"Steidl","year":"2012","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2024.05.005_bib0049","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1182\/blood.V99.4.1381","article-title":"Classical Hodgkin lymphoma is characterized by recurrent copy number gains of the short arm of chromosome 2","volume":"99","author":"Joos","year":"2002","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2024.05.005_bib0050","doi-asserted-by":"crossref","first-page":"3681","DOI":"10.1182\/blood-2002-08-2577","article-title":"Gains of 2p involving the REL locus correlate with nuclear c-Rel protein accumulation in neoplastic cells of classical Hodgkin lymphoma","volume":"101","author":"Barth","year":"2003","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2024.05.005_bib0051","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.3324\/haematol.12875","article-title":"Detection of genomic imbalances in microdissected Hodgkin and Reed-Sternberg cells of classical Hodgkin's lymphoma by array-based comparative genomic hybridization","volume":"93","author":"Hartmann","year":"2008","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2024.05.005_bib0052","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1182\/blood-2005-09-3843","article-title":"Chromosomal rearrangements involving the BCL3 locus are recurrent in classical Hodgkin and peripheral T-cell lymphoma","volume":"108","author":"Martin-Subero","year":"2006","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2024.05.005_bib0053","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1182\/blood-2009-12-257345","article-title":"Genome-wide copy number analysis of Hodgkin Reed-Sternberg cells identifies recurrent imbalances with correlations to treatment outcome","volume":"116","author":"Steidl","year":"2010","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2024.05.005_bib0054","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1200\/JCO.2016.66.4482","article-title":"PD-L1 and PD-L2 genetic alterations define classical Hodgkin lymphoma and predict outcome","volume":"34","author":"Roemer","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2024.05.005_bib0055","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1200\/JCO.2017.77.3994","article-title":"Major histocompatibility complex class II and programmed death ligand 1 expression predict outcome after programmed death 1 blockade in classic Hodgkin lymphoma","volume":"36","author":"Roemer","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2024.05.005_bib0056","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41572-019-0132-x","article-title":"Follicular lymphoma","volume":"5","author":"Carbone","year":"2019","journal-title":"Nat Rev Dis Primers"},{"key":"10.1053\/j.seminhematol.2024.05.005_bib0057","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/nrc.2016.40","article-title":"Mechanisms of human lymphoid chromosomal translocations","volume":"16","author":"Lieber","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"10.1053\/j.seminhematol.2024.05.005_bib0058","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1182\/blood.2020005289","article-title":"Genomic and epigenomic insights into the origin, pathogenesis, and clinical behavior of mantle cell lymphoma subtypes","volume":"136","author":"Nadeu","year":"2020","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2024.05.005_bib0059","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1182\/blood.2021011941","article-title":"A gene expression\u2013based model predicts outcome in children with intermediate-risk classical Hodgkin lymphoma","volume":"139","author":"Johnston","year":"2022","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2024.05.005_bib0060","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1158\/1078-0432.CCR-04-1869","article-title":"Outcome in Hodgkin's lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cells","volume":"11","author":"\u00c1lvaro","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminhematol.2024.05.005_bib0061","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3324\/haematol.11702","article-title":"Correlation of high numbers of intratumoral FOXP3+ regulatory T cells with improved survival in germinal center-like diffuse large B-cell lymphoma, follicular lymphoma and classical Hodgkin's lymphoma","volume":"93","author":"Tzankov","year":"2008","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2024.05.005_bib0062","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1182\/blood-2008-07-168096","article-title":"Molecular profiling of classical Hodgkin lymphoma tissues uncovers variations in the tumor microenvironment and correlations with EBV infection and outcome","volume":"113","author":"Chetaille","year":"2009","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2024.05.005_bib0063","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa0905680","article-title":"Tumor-associated macrophages and survival in classic Hodgkin's lymphoma","volume":"362","author":"Steidl","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2024.05.005_bib0064","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1038\/s41375-021-01204-6","article-title":"Molecular biology of Hodgkin lymphoma","volume":"35","author":"Weniger","year":"2021","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2024.05.005_bib0065","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1016\/S0002-9440(10)63027-1","article-title":"The transcription factor PU.1, necessary for B-cell development is expressed in lymphocyte predominance, but not classical Hodgkin's disease","volume":"159","author":"Torlakovic","year":"2001","journal-title":"Am J Pathol"},{"key":"10.1053\/j.seminhematol.2024.05.005_bib0066","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1038\/modpathol.3800622","article-title":"Expression profiling of transcription factors Pax-5, Oct-1, Oct-2, BOB.1, and PU.1 in Hodgkin's and non-Hodgkin's lymphomas: a comparative study using high throughput tissue microarrays","volume":"19","author":"McCune","year":"2006","journal-title":"Modern Pathol"},{"key":"10.1053\/j.seminhematol.2024.05.005_bib0067","doi-asserted-by":"crossref","first-page":"4609","DOI":"10.1182\/blood-2012-05-428896","article-title":"Analyzing primary Hodgkin and Reed-Sternberg cells to capture the molecular and cellular pathogenesis of classical Hodgkin lymphoma","volume":"120","author":"Tiacci","year":"2012","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2024.05.005_bib0068","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1158\/2326-6066.CIR-16-0201","article-title":"Classical Hodgkin lymphoma with reduced \u03b22M\/MHC class I expression is associated with inferior outcome independent of 9p24.1 status","volume":"4","author":"Roemer","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"10.1053\/j.seminhematol.2024.05.005_bib0069","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1182\/blood.2020008553","article-title":"Tumor and microenvironment response but no cytotoxic T-cell activation in classic Hodgkin lymphoma treated with anti-PD1","volume":"136","author":"Reinke","year":"2020","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2024.05.005_bib0070","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1038\/s41375-021-01421-z","article-title":"Reverted exhaustion phenotype of circulating lymphocytes as immune correlate of anti-PD1 first-line treatment in Hodgkin lymphoma","volume":"36","author":"Garcia-Marquez","year":"2022","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2024.05.005_bib0071","doi-asserted-by":"crossref","first-page":"e660","DOI":"10.1016\/S2352-3026(20)30221-0","article-title":"Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1\/2 trial","volume":"7","author":"Diefenbach","year":"2020","journal-title":"Lancet Haematol"},{"key":"10.1053\/j.seminhematol.2024.05.005_bib0072","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1080\/10428194.2022.2095623","article-title":"AFM13 in patients with relapsed or refractory classical Hodgkin lymphoma: final results of an open-label, randomized, multicenter phase II trial","volume":"63","author":"Sasse","year":"2022","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminhematol.2024.05.005_bib0073","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1200\/JCO.2011.39.9881","article-title":"Expression of FOXP3, CD68, and CD20 at diagnosis in the microenvironment of classical Hodgkin lymphoma is predictive of outcome","volume":"31","author":"Greaves","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2024.05.005_bib0074","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1309\/NB3947K383DJ0LQ2","article-title":"The ratio of FOXP3+ regulatory T cells to granzyme B+ cytotoxic T\/NK cells predicts prognosis in classical Hodgkin lymphoma and is independent of bcl-2 and MAL expression","volume":"128","author":"Kelley","year":"2007","journal-title":"Am J Clin Pathol"},{"key":"10.1053\/j.seminhematol.2024.05.005_bib0075","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1200\/JCO.2012.43.4589","article-title":"Gene expression-based model using formalin-fixed paraffin-embedded biopsies predicts overall survival in advanced-stage classical Hodgkin lymphoma","volume":"31","author":"Scott","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2024.05.005_bib0076","doi-asserted-by":"crossref","first-page":"3722","DOI":"10.1200\/JCO.2017.72.7925","article-title":"Prognostic model to predict post-autologous stem-cell transplantation outcomes in classical hodgkin lymphoma","volume":"35","author":"Chan","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2024.05.005_bib0077","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/ejh.12987","article-title":"An anergic immune signature in the tumor microenvironment of classical Hodgkin lymphoma is associated with inferior outcome","volume":"100","author":"Hollander","year":"2018","journal-title":"Eur J Haematol"},{"key":"10.1053\/j.seminhematol.2024.05.005_bib0078","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1038\/sj.onc.1205418","article-title":"Gene expression profiling defines molecular subtypes of classical Hodgkin's disease","volume":"21","author":"Devilard","year":"2002","journal-title":"Oncogene"},{"key":"10.1053\/j.seminhematol.2024.05.005_bib0079","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1182\/blood-2005-12-5125","article-title":"Tumor microenvironment and mitotic checkpoint are key factors in the outcome of classic Hodgkin lymphoma","volume":"108","author":"S\u00e1nchez-Aguilera","year":"2006","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2024.05.005_bib0080","doi-asserted-by":"crossref","unstructured":"Chan FC, Mottok A, Gerrie AS, et al. Prognostic model to predict post-autologous stem-cell transplantation outcomes in classical hodgkin lymphoma. J Clin Oncol 2017;35:3722\u20133733.","DOI":"10.1200\/JCO.2017.72.7925"},{"key":"10.1053\/j.seminhematol.2024.05.005_bib0081","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1111\/bjh.16777","article-title":"Validation of the RHL30 digital gene expression assay as a prognostic biomarker for relapsed Hodgkin lymphoma","volume":"190","author":"Calvente","year":"2020","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2024.05.005_bib0082","doi-asserted-by":"crossref","first-page":"3651","DOI":"10.1200\/JCO.2013.52.5410","article-title":"Dose-intensive response-based chemotherapy and radiation therapy for children and adolescents with newly diagnosed intermediate-risk Hodgkin lymphoma: a report from the children's oncology group study AHOD0031","volume":"32","author":"Friedman","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2024.05.005_bib0083","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/nm.3519","article-title":"An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage","volume":"20","author":"Newman","year":"2014","journal-title":"Nat Med"},{"key":"10.1053\/j.seminhematol.2024.05.005_bib0084","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/s41586-020-2140-0","article-title":"Integrating genomic features for non-invasive early lung cancer detection","volume":"580","author":"Chabon","year":"2020","journal-title":"Nature"},{"key":"10.1053\/j.seminhematol.2024.05.005_bib0085","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1038\/s41571-022-00660-y","article-title":"Circulating tumour DNA\u2014looking beyond the blood","volume":"19","author":"Tivey","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1053\/j.seminhematol.2024.05.005_bib0086","doi-asserted-by":"crossref","first-page":"4283","DOI":"10.1182\/blood-2002-01-0099","article-title":"The role of cytokines in classical Hodgkin lymphoma","volume":"99","author":"Skinnider","year":"2002","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2024.05.005_bib0087","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1111\/bjh.14317","article-title":"Biomarkers for evaluation of treatment response in classical Hodgkin lymphoma: comparison of sGalectin-1, sCD163 and sCD30 with TARC","volume":"175","author":"Plattel","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2024.05.005_bib0088","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1158\/1078-0432.CCR-12-2693","article-title":"Serum CD163 and TARC as disease response biomarkers in classical Hodgkin lymphoma","volume":"19","author":"Jones","year":"2013","journal-title":"Clinical Cancer Research"},{"key":"10.1053\/j.seminhematol.2024.05.005_bib0089","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1111\/his.14836","article-title":"The value of thymus and activation related chemokine immunohistochemistry in classic Hodgkin lymphoma diagnostics","volume":"82","author":"Kilsdonk","year":"2023","journal-title":"Histopathology"},{"key":"10.1053\/j.seminhematol.2024.05.005_bib0090","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1158\/1078-0432.CCR-12-2693","article-title":"Serum CD163 and TARC as disease response biomarkers in classical Hodgkin lymphoma","volume":"19","author":"Jones","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminhematol.2024.05.005_bib0091","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1182\/blood.2023020959","article-title":"Elevated serum TARC levels precede classic Hodgkin lymphoma diagnosis by several years","volume":"142","author":"Diepstra","year":"2023","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2024.05.005_bib0092","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1002\/hon.2775","article-title":"Early serum TARC reduction predicts prognosis in advanced-stage Hodgkin lymphoma patients treated with a PET-adapted strategy","volume":"38","author":"Viviani","year":"2020","journal-title":"Hematol Oncol"},{"key":"10.1053\/j.seminhematol.2024.05.005_bib0093","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1002\/jha2.432","article-title":"Blood-circulating EV-miRNAs, serum TARC, and quantitative FDG-PET features in classical Hodgkin lymphoma","volume":"3","author":"Drees","year":"2022","journal-title":"EJHaem"},{"key":"10.1053\/j.seminhematol.2024.05.005_bib0094","doi-asserted-by":"crossref","first-page":"2853","DOI":"10.1038\/s41375-022-01717-8","article-title":"Prognostic value of TARC and quantitative PET parameters in relapsed or refractory Hodgkin lymphoma patients treated with brentuximab vedotin and DHAP","volume":"36","author":"Driessen","year":"2022","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2024.05.005_bib0095","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1200\/JCO.2015.65.4194","article-title":"Evaluation of the risk of relapse in classical hodgkin lymphoma at event-free survival time points and survival comparison with the general population in British Columbia","volume":"34","author":"Hapgood","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2024.05.005_bib0096","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/S0002-9440(10)65424-7","article-title":"High expression of the CC chemokine TARC in Reed-Sternberg Cells: a possible explanation for the characteristic T-cell infiltrate in Hodgkin's lymphoma","volume":"154","author":"Van Den Berg","year":"1999","journal-title":"Am J Pathol"},{"key":"10.1053\/j.seminhematol.2024.05.005_bib0097","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1158\/0008-5472.CAN-08-2360","article-title":"Regulatory T cells recruited through CCL22\/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome","volume":"69","author":"Gobert","year":"2009","journal-title":"Cancer Res"},{"key":"10.1053\/j.seminhematol.2024.05.005_bib0098","doi-asserted-by":"crossref","first-page":"410","DOI":"10.3324\/haematol.2011.053199","article-title":"Plasma thymus and activation-regulated chemokine as an early response marker in classical Hodgkin's lymphoma","volume":"97","author":"Plattel","year":"2012","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2024.05.005_bib0099","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.1016\/S2352-3026(14)00039-8","article-title":"Non-invasive detection of genomic imbalances in Hodgkin\/Reed-Sternberg cells in early and advanced stage Hodgkin's lymphoma by sequencing of circulating cell-free DNA: a technical proof-of-principle study","volume":"2","author":"Vandenberghe","year":"2015","journal-title":"Lancet Haematol"},{"key":"10.1053\/j.seminhematol.2024.05.005_bib0100","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1182\/blood-2017-11-812073","article-title":"Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma","volume":"131","author":"Spina","year":"2018","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2024.05.005_bib0101","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/j.medj.2021.09.002","article-title":"In-depth cell-free DNA sequencing reveals genomic landscape of Hodgkin's lymphoma and facilitates ultrasensitive residual disease detection","volume":"2","author":"Sobesky","year":"2021","journal-title":"Med"},{"key":"10.1053\/j.seminhematol.2024.05.005_bib0102","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1038\/s41586-023-06903-x","article-title":"Distinct Hodgkin lymphoma subtypes defined by noninvasive genomic profiling","volume":"625","author":"Alig","year":"2024","journal-title":"Nature"},{"key":"10.1053\/j.seminhematol.2024.05.005_bib0103","first-page":"746","article-title":"Evaluation of apoptosis in classical Hodgkin's lymphoma comparing different methods","volume":"17","author":"Georgiadi","year":"2012","journal-title":"J Buon"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196324000696?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196324000696?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T23:35:43Z","timestamp":1730849743000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0037196324000696"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":103,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["S0037196324000696"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2024.05.005","relation":{},"ISSN":["0037-1963"],"issn-type":[{"value":"0037-1963","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Molecular biomarkers in classic Hodgkin lymphoma","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2024.05.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}